Free Trial

Harrow Q4 2023 Earnings Report

Harrow logo
$36.10 +2.25 (+6.65%)
As of 01/21/2025 04:00 PM Eastern

Harrow EPS Results

Actual EPS
-$0.27
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Harrow Revenue Results

Actual Revenue
$36.36 million
Expected Revenue
$37.65 million
Beat/Miss
Missed by -$1.29 million
YoY Revenue Growth
N/A

Harrow Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Harrow Earnings Headlines

Harrow announces Amir Shojaei, PharmD, PhD joins as CSO
Harrow Health (HROW) Gets a Buy from Craig-Hallum
January 29th - the next big trading catalyst to watch
Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO the market… Unleashing more explosive moves than ever before.
Those Derisked Baby Bonds Of Harrow, Inc.
See More Harrow Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Harrow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harrow and other key companies, straight to your email.

About Harrow

Harrow (NASDAQ:HROW) operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

View Harrow Profile

More Earnings Resources from MarketBeat